Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice
Eiki Takimoto, … , Michael E. Mendelsohn, David A. Kass
Eiki Takimoto, … , Michael E. Mendelsohn, David A. Kass
Published January 5, 2009
Citation Information: J Clin Invest. 2009;119(2):408-420. https://doi.org/10.1172/JCI35620.
View: Text | PDF
Research Article Cardiology

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

  • Text
  • PDF
Abstract

The heart initially compensates for hypertension-mediated pressure overload by enhancing its contractile force and developing hypertrophy without dilation. Gq protein–coupled receptor pathways become activated and can depress function, leading to cardiac failure. Initial adaptation mechanisms to reduce cardiac damage during such stimulation remain largely unknown. Here we have shown that this initial adaptation requires regulator of G protein signaling 2 (RGS2). Mice lacking RGS2 had a normal basal cardiac phenotype, yet responded rapidly to pressure overload, with increased myocardial Gq signaling, marked cardiac hypertrophy and failure, and early mortality. Swimming exercise, which is not accompanied by Gq activation, induced a normal cardiac response, while Rgs2 deletion in Gαq-overexpressing hearts exacerbated hypertrophy and dilation. In vascular smooth muscle, RGS2 is activated by cGMP-dependent protein kinase (PKG), suppressing Gq-stimulated vascular contraction. In normal mice, but not Rgs2–/– mice, PKG activation by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardiac hypertrophy, inhibiting Gq-coupled stimuli. Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both genotypes, but PKG plasma membrane translocation was more transient in Rgs2–/– myocytes than in controls and was unaffected by PDE5 inhibition. Thus, RGS2 is required for early myocardial compensation to pressure overload and mediates the initial antihypertrophic and cardioprotective effects of PDE5 inhibitors.

Authors

Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass

×

Figure 2

Rgs2–/– hearts display chamber dilation and fail to compensate to TAC.

Options: View larger image (or click on image) Download as PowerPoint

Rgs2–/– hearts display chamber dilation and fail to compensate to TAC.
...
(A) Echocardiographic data before and after 1 wk TAC (n = 7 per group). LV-Dd, LV end-diastolic dimension; LV-Ds, LV end-systolic dimension. #P < 0.05 versus Rgs2+/+ 1 wk TAC. (B) Representative PV loops during preload reduction by inferior vena cava occlusion in sham (thick line) and 1 wk TAC animals (thin dotted line). Steepness of left upper relation (end-systolic elastance [Ees]) reflected contractile function and was enhanced after TAC in Rgs2+/+ mice, but unaltered with a right-shift (remodeling) of the relation in Rgs2–/– mice. (C) Peak systolic LV pressure (LVP sys) and effective arterial elastance (Ea; an index of total ventricular afterload). Rgs2–/– mice had somewhat higher basal afterload, but both genotypes had similarly increased afterload after 1 wk TAC (n = 5–7 per group). P value shown is for interaction of genotype and condition. *P < 0.05 versus sham; †P < 0.05 versus Rgs2+/+ sham. (D) Summary data obtained from PV loop analysis shown in bar graphs. P values shown are for interaction of genotype and condition (2-way ANOVA). *P ≤ 0.001, †P < 0.05 versus sham. V100, volume position (end-systolic volume at common end-systolic pressure — 100 mmHg — derived from end-systolic PV relation); dP/dtmax, peak rate of LV pressure rise; PRSW, preload recruitable stroke work; dP/dtmin, peak rate of LV pressure decline; Tau, relaxation time constant; SV, stroke volume; CO, cardiac output. P values shown are for interaction of genotype and condition (2-way ANOVA). *P < 0.05, §P = 0.06 versus sham; †P < 0.05 versus corresponding Rgs2+/+ TAC and Rgs2–/– sham (1-way ANOVA).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts